BioStock studio: Aptahem's CSO on the sepsis candidate Apta-1
Luiza Jedlina, CSO and co-founder of Aptahem, visited the BioStock Studio at Medicon Village in Lund to talk about the company’s leading drug candidate Apta-1. Jedlina, who holds a PhD in molecular parasitology and immunology as well as a master’s degree in toxicology, has been instrumental in the establishment of Apta-1 as a potential treatment for “The Silent Killer”, sepsis.
Watch the interview with Aptahem's CSO Luiza Jedlina at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/